Table of Contents Author Guidelines Submit a Manuscript

Dysregulated Metabolism in Hepatic Diseases

Call for Papers

The liver is considered as the most important organ associated with metabolism of xenobiotic and endogenous compounds. Notably, hepatic metabolism has substantial crosstalk with multiple organs and pathways (liver-gut axis and liver-brain axis). It is important that some hepatic diseases such as nonalcoholic fatty liver diseases (NAFLD) have a serious impact on drug metabolism and glucose and lipid homeostasis. On the other hand, disturbance in metabolism homeostasis is also profoundly involved in the pathogenesis of hepatic diseases.

This special issue will integrate the latest studies and reviews addressing dysregulated metabolic pathways underlying the progression of hepatic diseases and their interaction. Drug/xenobiotic-mediated metabolic dysregulation and its role in liver injury are also highly welcomed.

Potential topics include but are not limited to the following:

  • Metabolic diseases and hepatic diseases
  • Enterohepatic circulation disorders and liver-gut diseases
  • Bile acids metabolism in hepatic diseases
  • Drug disposition alterations under hepatic diseases
  • Adverse Drug Reactions (ADRs) associated with liver injury
  • Application of metabonomics in hepatic diseases
  • Glucose and lipid metabolism in hepatic disease
  • CYP450s enzymes and drug transporters in hepatic diseases
  • Gut microbiota and hepatic diseases interaction
  • Nutrition metabolism in hepatic diseases
  • PKPD or QSP (Quantitative Systems Biology) model for xenobiotic/endogenous metabolism in hepatic diseases

Authors can submit their manuscripts through the Manuscript Tracking System at https://mts.hindawi.com/submit/journals/ijh/dmhd/.

Submission DeadlineFriday, 27 July 2018
Publication DateDecember 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

  • Can Liu, University of North Carolina at Chapel Hill, Chapel Hill, USA

Guest Editors

  • Jia Li, Food and Drug Administration, Silver Spring, USA
  • Yunli Yu, The Second Affiliated Hospital of Soochow University, Suzhou, China